IP Library Granted Patent US 8,680,051
Granted Patent B2
US 8,680,051 · App. 12/643,008 · Granted Mar 25, 2014

Method of ameliorating symptoms of type 1-diabetes using GABA related compounds and GLP-1/exendin-4 compounds

Inventors: Qinghua Wang (Toronto, CA); Soltani Nepton (Thornhill, CA)
Assignee: Qinghua Wang
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,680,051
App. No.
12/643,008
Granted
Mar 25, 2014
Kind
B2
Abstract

A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals.

Claims (6)

1. A method of ameliorating symptoms of type 1 diabetes (T1D), said method comprising administering a composition comprising an effective amount of:

a. gamma-amino butyric acid (GABA) or a pharmaceutically acceptable salt thereof; and

b. exendin-4 (Ex4) of SEQ ID NO:2.

2. The method at claim 1 , wherein said composition is administered by a method selected from topical administration, oral administration, aerosol administration, intraperitoneal injection, intravenous injection and/or intramuscular injection.

3. The method of claim 1 , wherein the dosage of the composition is 0.01-10 mmol of GABA per kg body weight and 0.02 to 1000 nmol of the Ex4 per kg body weight.

4. The method of claim 1 , wherein the dosage of the composition is between about 0.002-2 mg of GABA per kg body weight and 0.2-1000 nmol of the Ex4 per kg body weight.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 061767 FRAME: 0903. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Jan 4, 2023
From: KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD.
To: GUANGZHOU INNOGEN PHARMACEUTICAL GROUP CO., LTD.
Reel/Frame 062273/0483 →
CHANGE OF NAME Recorded Oct 25, 2022
From: KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD.
To: GUANGZHOU INNOGEN PHARMCEUTICAL GROUP CO., LTD.
Reel/Frame 061767/0903 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2020
From: WANG, QINGHUA
To: KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD.
Reel/Frame 054759/0655 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2011
From: SOLTANI, NEPTON
To: WANG, QINGHUA
Reel/Frame 025592/0023 →
Continuity (2)
Provisional Application 61138957 · Dec 19, 2008
Related Publication 20100166675A1 · Jul 1, 2010